Cargando…

Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) patients harboring a KRAS mutation have unfavorable therapeutic outcomes with chemotherapies, and the mutation also renders tolerance to immunotherapies. There is an unmet need for a new strategy for overcoming immunosuppression in KRAS-mutant NSCLC. The recently d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chao, Yi-Chun, Lee, Kang-Yun, Wu, Sheng-Ming, Kuo, Deng-Yu, Shueng, Pei-Wei, Lin, Cheng-Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199131/ https://www.ncbi.nlm.nih.gov/pubmed/34073318 http://dx.doi.org/10.3390/ijms22115649

Ejemplares similares

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer
por: Feng, Hui‐Bo, et al.
Publicado: (2021)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism
por: Shueng, Pei-Wei, et al.
Publicado: (2022)

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
por: Xie, Mingying, et al.
Publicado: (2021)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
por: Minchom, Anna, et al.
Publicado: (2017)

Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity
por: Lee, Jungeun, et al.
Publicado: (2022)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023)

Integrated multi-omics characterization of KRAS mutant colorectal cancer
por: Chong, Wei, et al.
Publicado: (2022)

The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials
por: Chen, Wei, et al.
Publicado: (2022)

Targeting oxidative pentose phosphate pathway prevents recurrence in mutant Kras colorectal carcinomas
por: Gao, WenChao, et al.
Publicado: (2019)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis
por: Weng, Ching-Chieh, et al.
Publicado: (2018)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
por: Adderley, Helen, et al.
Publicado: (2019)

Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer
por: Lin, Bo, et al.
Publicado: (2020)

BladderScan Feedback Method in Predicting Bladder Filling for Prostate Radiotherapy: A Prospective Study
por: Kuo, Deng-Yu, et al.
Publicado: (2021)

Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
por: Wang, Yadong, et al.
Publicado: (2022)

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014)

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
por: Uras, Iris Z., et al.
Publicado: (2020)

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
por: Zhou, Qiming, et al.
Publicado: (2023)

Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS
por: Narvaez, Ana J., et al.
Publicado: (2017)

Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis
por: Hung, Wei-Chia, et al.
Publicado: (2020)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Downregulation of Notch Signaling in Kras-Induced Gastric Metaplasia
por: Chung, Wen-Cheng, et al.
Publicado: (2019)

The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy
por: Shu, Chun-Lu, et al.
Publicado: (2022)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
por: Konen, Jessica M., et al.
Publicado: (2019)

Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression
por: Kwack, Won Gun, et al.
Publicado: (2020)

A combinatorial strategy for treating KRAS mutant lung cancer
por: Manchado, Eusebio, et al.
Publicado: (2016)

Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
por: Amanam, Idoroenyi, et al.
Publicado: (2020)

SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer
por: Wang, Xiaowen, et al.
Publicado: (2021)

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
por: Maroni, Giorgia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u4m10o6v9u7jdmfdmb8b6mpfb8